← Back to Clinical Trials
Recruiting NCT05323916

NCT05323916 Comprehensive Intensive Stroke Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05323916
Status Recruiting
Phase
Sponsor Charles University, Czech Republic
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 280 participants
Start Date 2022-05-01
Primary Completion 2025-06-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Neuroproprioceptive "facilitation, inhibition"Technology based physical therapyEffectively managed rehabilitation implementing the recommendations of the World Health Organization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 280 participants in total. It began in 2022-05-01 with a primary completion date of 2025-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, the investigators aim to assess the effectiveness of the Comprehensive Intensive Rehabilitation Program After Stroke implementing the International Classification of Functioning, Disability and Health model, and to compare it with two cohorts receiving Comprehensive Intensive Rehabilitation Program After Stroke of the same length but different in physical therapy content (program implementing modern technological approach and neuroproprioceptive "facilitation and inhibition"). Moreover, control group will undergo standard care.

Eligibility Criteria

Inclusion Criteria: * adults * after first ischemic stroke * early sub-acute phase * slight to moderately severe disability \[2 - 4 on the Modified Rankin Scale\] * 0 - 2 on the Pre-Stroke Modified Rankin Score * potential to accept 4 hours of comprehensive rehabilitation per day and to profit from physiotherapy * minimal or moderate motor deficit of upper or lower extremities (on NIHSS Item 5 or 6 scores 1-3 points) * able to perform activities of daily living prior to stroke event (0 - 2 on the Pre-Stroke Modified Rankin Score) * Czech is participants' native language or its knowledge is at the level of the mother tongue Exclusion Criteria: * low level of consciousness (vegetative state and/or minimally conscious state); severe cognitive decline that would interfere with administration of the tests, premorbid illiteracy, severe visual and/or auditory deficit that would prevent proper completion of the tests * behavioural disorders and/or lack of cooperation with therapist * severe medical problems with a poor prognosis, (e.g., severe frailty, advanced and incurable cancer, fracture, cardiovascular disorders as chronic heart failure NYHA III, IV, symptomatic coronary artery disease Angina Severity Class III, IV, respiratory insufficiency as chronic obstructive pulmonary disease GOLD IV, and other severe disease)

Contact & Investigator

Central Contact

Kamila Řasová, Dr.

✉ kamila.rasova@gmail.com

📞 +420604511416

Principal Investigator

Kamila Řasová, Dr.

PRINCIPAL INVESTIGATOR

Charles University, Czech Republic

Frequently Asked Questions

Who can join the NCT05323916 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05323916 currently recruiting?

Yes, NCT05323916 is actively recruiting participants. Contact the research team at kamila.rasova@gmail.com for enrollment information.

Where is the NCT05323916 trial being conducted?

This trial is being conducted at Prague, Czechia.

Who is sponsoring the NCT05323916 clinical trial?

NCT05323916 is sponsored by Charles University, Czech Republic. The principal investigator is Kamila Řasová, Dr. at Charles University, Czech Republic. The trial plans to enroll 280 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology